Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe hemophilia by roughly 90%, regardless of whether they had type A or B, and whether they had developed antibodies to recombinant clotting factors.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Actinium, Adagene, Affimed, Agios, Allogene, Annexon, Aprea, Arcellx, Astrazeneca, Autolus, Beigene, Editas, Emmaus, Epizyme, Equillium, Fate, Freeline, Gamida, GBT, Genentech, Glycomimetics, GSK, Hutchmed, I-Mab, Imara, Kite, Kura, Sutro.
PERTH, Australia – In the second multi-billion-dollar pharma merger this week, CSL Ltd. has announced plans to buy Vifor Pharma Ltd. for an equity value of $11.7 billion. It’s also the second largest biopharma merger of 2021, a whisker above Merck & Co Inc.’s $11.5 billion acquisition of Acceleron Pharma Inc. in November, although way off Astrazeneca plc’s $39 billion buy of Alexion Pharmaceuticals Inc. in July.
Clonal hematopoiesis of indeterminate potential (CHIP) was associated with a 35% reduced risk of Alzheimer's disease (AD) in studies presented at the plenary session of the American Society of Hematology (ASH) annual meeting on Sunday.
RSS
